Recent 8-K filings for MAIA

• May 22, 2026, 6:03 AM ET other materiality 0.10 neutral item 5.07

  MAIA Biotechnology shareholders re-elect two directors, ratify Grant Thornton at 2026 annual meeting

  Stockholders voted to re-elect Louie Ngar Yee (16.7M for, 8.8M withheld) and Steven Chaouki (25.1M for, 345.7K withheld) as Class I directors for three-year terms.

• May 14, 2026, 5:02 PM ET other material materiality 0.45 neutral item 1.02

  MAIA Biotechnology terminates ATM equity offering agreement after raising ~$5.68M

  Suspended sales and gave notice to terminate At The Market Offering Agreement with H.C. Wainwright, effective 7 business days after May 14, 2026.

• April 16, 2026, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  MAIA activates first U.S. site for Phase 2 THIO-101 trial in advanced NSCLC

  First U.S. site activated at Summit Medical Group (NJ); four more U.S. sites planned in 2026.

• April 8, 2026, 7:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  MAIA Biotechnology: $33M raise fully funds pivotal Phase 3 trial for ateganosine in NSCLC

  Net proceeds from $33M March 2026 common stock offering expected to fully fund pivotal Phase 3 trial (THIO-104) for ateganosine in third-line NSCLC.

• April 2, 2026, 7:59 PM ET other material materiality 0.50 neutral item 5.02item 9.01

  MAIA Biotechnology awards $362,610 in bonuses to CEO and Head of Finance for capital raise

  CEO Vlad Vitoc receives one-time bonus of $312,610 for efforts in recent capital raise.

• March 31, 2026, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  MAIA reports OS >2 years for 8 NSCLC patients; 1 at 33 months in 3L

  Eight patients treated with ateganosine + cemiplimab in Phase 2 THIO-101 trial had overall survival exceeding 24 months.

• March 27, 2026, 7:59 PM ET other material materiality 0.65 positive item 7.01item 8.01item 9.01

  MAIA presents THIO-101 data at ELCC showing sustained response in relapsed NSCLC

  Poster presented at European Lung Cancer Congress 2026 in Copenhagen on March 27, 2026.

• March 4, 2026, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  MAIA Biotechnology closes $30M public offering of 20M shares at $1.50/sh

  Closed underwritten public offering of 20M shares at $1.50/sh, gross proceeds $30M.

• February 24, 2026, 6:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  MAIA Biotechnology updates on Phase 3 ateganosine trial in NSCLC; Fast Track status

  Ongoing Phase 3 full approval trial of ateganosine for third-line non-small cell lung cancer.

• January 20, 2026, 6:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  MAIA Biotechnology updates ateganosine program, targeting early commercial approval in NSCLC

  Ateganosine obtained FDA Fast Track designation for NSCLC in 2025; company expects potential Accelerated Approval and Priority Review.

• January 13, 2026, 6:59 PM ET other material materiality 0.20 neutral item 7.01item 8.01item 9.01

  MAIA Biotechnology presents at Biotech Showcase; no specific financial updates disclosed

  Management presented at Biotech Showcase in San Francisco on January 13, 2026.

• December 17, 2025, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 8.01item 9.01

  MAIA Biotechnology announces $1.51M private placement of common stock and warrants

  Gross proceeds ~$1.51M from 1,233,488 shares at $1.224 each, with warrants exercisable at $1.36.

• December 11, 2025, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  MAIA dosed first patient in THIO-104 Phase 3 trial of ateganosine for third-line NSCLC

  First patient dosed in THIO-104 Phase 3 pivotal trial evaluating ateganosine + CPI vs chemo in third-line NSCLC.

• December 10, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  MAIA touts $50B immunotherapy market; ateganosine gets Fast Track for NSCLC, Phase 3 starting

  FDA Fast Track Designation for ateganosine in NSCLC patients resistant to immunotherapy and chemotherapy.

• November 21, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  MAIA Biotech highlights 12 patients enrolled in THIO-101 Phase 2 expansion, 30-month survival at SITC 2025

  12 patients enrolled to date in Phase 2 THIO-101 expansion trial; sites now open in EMA countries, Turkey, and Taiwan.

• November 20, 2025, 6:59 PM ET other material materiality 0.55 positive item 8.01item 9.01

  MAIA starts Romania enrollment for Phase 2 THIO-101 Part C; 38% ORR vs standard 6% cited

  CEO presented at Smart Diaspora 2025; Romania begins screening patients for THIO-101 Part C.

• November 7, 2025, 6:59 PM ET other material materiality 0.50 neutral item 8.01item 9.01

  MAIA Biotechnology presents THIO-104 and THIO-101 posters at SITC 2025 for NSCLC trials

  THIO-104 Phase 3 study of ategano sine (THIO) sequenced with ICI vs SOC chemo in ICI-resistant advanced NSCLC presented Nov 7.

• October 27, 2025, 7:59 PM ET other material materiality 0.30 neutral item 8.01item 9.01

  MAIA enrolls first five patients in THIO-101 Part C expansion in Taiwan and Turkey

  Presented trial-in-progress poster on ateganosine (THIO) plus ICI for advanced NSCLC at AACR-NCI-EORTC conference, Oct 22-26, 2025 in Boston.

• October 24, 2025, 7:59 PM ET other material materiality 0.30 neutral item 8.01item 9.01

  MAIA presents THIO-101 Phase 2 poster at AACR-NCI-EORTC conference on Oct 24, 2025

  Poster on Ateganosine (THIO) + ICI in advanced NSCLC patients resistant to prior ICI and chemotherapy.

• October 23, 2025, 7:59 PM ET other material materiality 0.70 positive item 7.01item 8.01item 9.01

  MAIA reports 30-month (912-day) survival for a Phase 2 NSCLC patient; ESMO posters presented

  One third-line NSCLC patient on ateganosine (THIO) survived 30 months/912 days as of Sep 17, 2025.

• October 14, 2025, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 3.02item 8.01

  MAIA Biotechnology announces $736,600 private placement of common stock and warrants

  Private placement of 603,769 shares at $1.22 per share with warrants to purchase 603,769 shares at $1.52.

• October 7, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  MAIA Biotechnology to hold up to 90% of liquid assets in Bitcoin, Ethereum, and USDC

  Board authorized up to 90% of liquid assets to be held in cryptocurrencies: BTC, ETH, and USDC.

• September 30, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 8.01item 9.01

  MAIA Biotechnology announces $2.25M private placement of stock and warrants

  Gross proceeds ~$2.25M from sale of 1,733,766 shares at $1.30; one warrant per share at $1.57 exercise price.

• September 24, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  MAIA Biotechnology awarded $2.3M NIH grant for THIO-101 Phase 2 trial in NSCLC

  NIH grant of $2.3M supports expansion of THIO-101 Phase 2 trial evaluating ateganosine as third-line NSCLC treatment.

• September 18, 2025, 7:59 PM ET other material materiality 0.40 neutral item 1.01item 3.02item 9.01

  MAIA Biotechnology induces warrant exercise at $1.30/share for ~$573K gross proceeds

  Entered inducement letters for holders to exercise 440,503 warrants at reduced price of $1.30/share.

• September 12, 2025, 7:59 PM ET other material materiality 0.10 neutral item 8.01item 9.01

  MAIA Biotechnology posts updated business presentation on website

  Presentation posted September 12, 2025; no specific changes disclosed.

• September 11, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  MAIA reports positive THIO-101 Phase 2 data: PFS 5.6 mo, OS 17.8 mo in 3L NSCLC

  Estimated median PFS of 5.6 months (180 mg dose) vs 2.5 months standard of care in third-line NSCLC.

• September 8, 2025, 7:59 PM ET other material materiality 0.50 positive item 7.01item 8.01item 9.01

  MAIA presents Phase 2 THIO-101 poster at WCLC showing PFS improvement in advanced NSCLC

  Poster titled 'Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-resistant aNSCLC: Improvement in PFS' presented at 2025 WCLC on Sept 7, 2025.

• August 13, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  MAIA Biotechnology granted European patent covering ateganosine-based telomere-targeting anticancer therapy

  European Patent Office grants patent for ateganosine-based analogues for telomere-targeting anticancer therapy.

• July 28, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  MAIA Biotech gets FDA Fast Track for ateganosine in NSCLC; Phase 2 data shows 17.8-month median OS

  FDA granted Fast Track designation for ateganosine (THIO) for treatment of non-small cell lung cancer.

• July 17, 2025, 7:59 PM ET other material materiality 0.50 positive item 8.01item 9.01

  MAIA announces peer-reviewed publication validating second-gen ateganosine prodrugs

  Data published in Nucleic Acids Research (Vol. 53, Issue 12, June 26, 2025) on novel telomere-targeting dinucleotide prodrugs.

• July 9, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  MAIA doses first patient in Phase 2 expansion for ateganosine in advanced NSCLC; median OS 17.8 months

  First patient dosed in Taiwan in THIO-101 expansion for 3L NSCLC after CPI/chemo failure.

• June 26, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01

  MAIA Biotechnology enters $587,905 stock purchase agreement with Prevail Partners for Phase 3 THIO trial

  Total purchase amount up to $587,905; monthly payments equal to 33% of invoices for Phase 3 THIO trial services provided by Prevail affiliate InfoWorks.

• June 24, 2025, 7:59 PM ET other material materiality 0.55 positive item 8.01item 9.01

  MAIA appoints HCC specialists to SAB; Phase 2 trial enrollment expected by year-end 2025

  Appointed Drs. Claudia Fulgenzi and David J. Pinato to SAB; both are HCC clinician-scientists.

• June 18, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  MAIA signs master clinical supply agreement with Roche for ateganosine-atezolizumab combo studies

  Agreement supports future studies combining MAIA's ateganosine (THIO) with Roche's atezolizumab (Tecentriq) for multiple hard-to-treat cancers.

• June 17, 2025, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 3.02item 9.01

  MAIA Biotechnology raises ~$329K via warrant exercise inducement at reduced $1.50/share

  On June 17, 2025, MAIA entered inducement letters with holders of four warrant series to exercise for cash at reduced exercise price of $1.50 per share.

• June 5, 2025, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  MAIA reports 17.8-month median OS in NSCLC trial; new partial response after 20 months

  Median overall survival of 17.8 months for 22 third-line NSCLC patients, nearly triple the 5-6 month SOC.

• June 2, 2025, 7:59 PM ET other material materiality 0.65 neutral item 7.01item 8.01item 9.01

  MAIA presents Phase 2 THIO-101 NSCLC efficacy data at ASCO 2025

  Poster presented at 2025 ASCO Annual Meeting on May 31 showing efficacy from Phase 2 THIO-101 trial.

• May 28, 2025, 7:59 PM ET other material materiality 0.40 neutral item 1.01item 3.02item 8.01

  MAIA Biotechnology closes $695K private placement of stock and warrants for THIO-101 trial

  Sold 463,332 shares and warrants at $1.50/share; warrants exercisable at $1.71, 5-year term, 6-month lockout.

• May 23, 2025, 7:59 PM ET other material materiality 0.55 neutral item 5.03item 9.01

  MAIA Biotechnology increases authorized shares from 70M to 150M after stockholder approval

  Stockholders approved amendment to certificate of incorporation on May 22, 2025.

• May 22, 2025, 7:59 PM ET other material materiality 0.50 neutral item 5.07item 8.01item 9.01

  MAIA Biotechnology stockholders approve increase in authorized common shares to 150M

  Stockholders re-elected Class III directors Jean-Manassé Theagène and Stan V. Smith for three-year terms.

• May 6, 2025, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 3.02item 8.01item 9.01

  MAIA raises $1.08M in private placement; warrants corrected to 1-year lockout, 6-year term

  719,999 shares sold at $1.50/share; each with a warrant to buy one share at $2.05.

• April 22, 2025, 7:59 PM ET other material materiality 0.25 neutral item 8.01item 9.01

  MAIA Biotechnology posts business presentation; no specific details in filing text

  Company made business presentation available on its website on April 22, 2025.

• April 1, 2025, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  MAIA Biotechnology details 2025 clinical milestones; potential FDA filings in 2026 for THIO

  Lead compound THIO is the only clinical-stage telomere-targeting anticancer agent.

• March 28, 2025, 7:59 PM ET other material materiality 0.75 neutral item 7.01item 9.01

  MAIA presents Phase 2 THIO-101 efficacy data in advanced NSCLC at ELCC 2025

  Efficacy data from Phase 2 THIO-101 trial presented at European Lung Cancer Congress 2025 on March 28, 2025.

• March 26, 2025, 7:59 PM ET other material materiality 0.30 neutral item 8.01item 9.01

  MAIA Biotechnology reduces ATM offering capacity from $30M to $11.2M

  Maximum aggregate offering price reduced from $30M to $11.2M under ATM with H.C. Wainwright.

• March 21, 2025, 7:59 PM ET other materiality 0.00 neutral item 8.01item 9.01

  MAIA Biotechnology posts business presentation; no substantive updates disclosed

  Company made a business presentation available on its website on March 21, 2025.

• March 19, 2025, 7:59 PM ET regulatory materiality 0.30 positive item 8.01item 9.01

  MAIA Biotech gets USAN approval for 'ateganosine' as generic name for THIO in NSCLC

  USAN Council approved nonproprietary name 'ateganosine' for lead molecule THIO, a telomere-targeting anticancer agent.

• February 27, 2025, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  MAIA plans Phase 3 pivotal trial of THIO+CPI vs chemo in NSCLC patients

  Phase 3 trial THIO-104 to enroll up to 300 patients with third-line NSCLC.

• February 25, 2025, 6:59 PM ET other material materiality 0.50 neutral item 1.01item 3.02item 8.01item 9.01

  MAIA Biotechnology raises ~$1.43M private placement, total $4.1M from two deals

  952,300 shares at $1.50 each; warrants exercisable at $1.85 for 6 years, starting 1 year post-issuance.

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

24 positive 0 negative 26 neutral

source · MAIA on sec.gov